National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.

Blumental S, Lajot A, Vandromme M, Lafort Y, Dockx Y, Denayer S, Wampers A, Nebbioso A, Tilmanne A, Mignon C, Tuerlinckx D, Rigolle H, Matthijs I, Vandersnickt J, Hellinckx J, Dewulf J, Coppens K, Van Hoorenbeeck K, Vanlede K, Winters L, Seyler L, Parsy MP, Reynders M, Balcaen M, Urbina M, Dauby N, Chatzis O, Naesens R, Dorval S, Ternest S, Vanspeybroeck S, Goetghebuer T, Van Ackere T, Selimaj Kontoni V, El Bitar W, Holemans X, Bruyere Y, Van Brusselen D, De Mot L, Raes M

Open source

DOI: 10.1186/s12879-026-13419-y
Published: 2026 May 20
Container: BMC infectious diseases
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12879-026-13419-y,
  title = {National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.},
  author = {Blumental S and Lajot A and Vandromme M and Lafort Y and Dockx Y and Denayer S and Wampers A and Nebbioso A and Tilmanne A and Mignon C and Tuerlinckx D and Rigolle H and Matthijs I and Vandersnickt J and Hellinckx J and Dewulf J and Coppens K and Van Hoorenbeeck K and Vanlede K and Winters L and Seyler L and Parsy MP and Reynders M and Balcaen M and Urbina M and Dauby N and Chatzis O and Naesens R and Dorval S and Ternest S and Vanspeybroeck S and Goetghebuer T and Van Ackere T and Selimaj Kontoni V and El Bitar W and Holemans X and Bruyere Y and Van Brusselen D and De Mot L and Raes M},
  year = {2026},
  journal = {BMC infectious diseases},
  doi = {10.1186/s12879-026-13419-y},
  url = {https://doi.org/10.1186/s12879-026-13419-y}
}

RIS

TY  - JOUR
TI  - National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.
AU  - Blumental S
AU  - Lajot A
AU  - Vandromme M
AU  - Lafort Y
AU  - Dockx Y
AU  - Denayer S
AU  - Wampers A
AU  - Nebbioso A
AU  - Tilmanne A
AU  - Mignon C
AU  - Tuerlinckx D
AU  - Rigolle H
AU  - Matthijs I
AU  - Vandersnickt J
AU  - Hellinckx J
AU  - Dewulf J
AU  - Coppens K
AU  - Van Hoorenbeeck K
AU  - Vanlede K
AU  - Winters L
AU  - Seyler L
AU  - Parsy MP
AU  - Reynders M
AU  - Balcaen M
AU  - Urbina M
AU  - Dauby N
AU  - Chatzis O
AU  - Naesens R
AU  - Dorval S
AU  - Ternest S
AU  - Vanspeybroeck S
AU  - Goetghebuer T
AU  - Van Ackere T
AU  - Selimaj Kontoni V
AU  - El Bitar W
AU  - Holemans X
AU  - Bruyere Y
AU  - Van Brusselen D
AU  - De Mot L
AU  - Raes M
PY  - 2026
JO  - BMC infectious diseases
DO  - 10.1186/s12879-026-13419-y
UR  - https://doi.org/10.1186/s12879-026-13419-y
ER  -

APA

S, B., A, L., M, V., Y, L., Y, D., S, D., A, W., A, N., A, T., C, M., D, T., H, R., I, M., J, V., J, H., J, D., K, C., K, V. H., K, V., L, W., L, S., MP, P., M, R., M, B., M, U., N, D., O, C., R, N., S, D., S, T., S, V., T, G., T, V. A., V, S. K., W, E. B., X, H., Y, B., D, V. B., L, D. M., & M, R. (2026). National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.. BMC infectious diseases. https://doi.org/10.1186/s12879-026-13419-y

Source records

pubmed · retrieved 2026-09-26T23:03:31.855Z